Josef Ozer, Ph.D.

Affiliations: 
Pharmacology Boston University School of Medicine, Boston, MA 
Area:
Pharmacology
Google:
"Josef Ozer"
Mean distance: 106866 (cluster 11)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ratner MH, Farb DH, Ozer J, et al. (2014) Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides. Interdisciplinary Toxicology. 7: 123-33
Brodfuehrer J, Rankin A, Edmonds J, et al. (2014) Quantitative analysis of target coverage and germinal center response by a CXCL13 neutralizing antibody in a T-dependent mouse immunization model. Pharmaceutical Research. 31: 635-48
Wang M, Defranco D, Wright K, et al. (2012) Decreased subcutaneous bioavailability of an Oxyntomodulin analog in a controlled release formulation could be caused by skin metabolism in rats Journal of Bioequivalence and Bioavailability. 4: 69-77
Wang M, Defranco D, Wright K, et al. (2012) Decreased subcutaneous bioavailability of an Oxyntomodulin analog in a controlled release formulation could be caused by skin metabolism in rats Journal of Bioequivalence and Bioavailability. 4: 69-77
Zhang Y, Li N, Brown PW, et al. (2011) Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. Rapid Communications in Mass Spectrometry : Rcm. 25: 1715-24
Chetty RK, Ozer JS, Lanevschi A, et al. (2010) A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association. Clinical Pharmacology and Therapeutics. 88: 260-2
Ozer JS, Chetty R, Kenna G, et al. (2010) Recommendations to qualify biomarker candidates of drug-induced liver injury. Biomarkers in Medicine. 4: 475-83
Ozer JS, Dieterle F, Troth S, et al. (2010) A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology. 28: 486-94
Vaidya VS, Ozer JS, Dieterle F, et al. (2010) Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology. 28: 478-85
Yu Y, Jin H, Holder D, et al. (2010) Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnology. 28: 470-7
See more...